Caroline Bodet-Milin

List of Publications by Year
in descending order

108 papers	3,477 citations	126907 33 h-index	155660 55 g-index
114 all docs	114 docs citations	114 times ranked	4216 citing authors

#	Article	IF	Citations
1	Prospective Evaluation of Magnetic Resonance Imaging and [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. Journal of Clinical Oncology, 2017, 35, 2911-2918.	1.6	247
2	Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Advances, 2020, 4, 5607-5615.	5.2	222
3	Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica, 2008, 93, 471-472.	3.5	130
4	Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkinâ€™s lymphoma: a reflection of disease infiltration or just inflammation?. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1813-1821.	6.4	111
5	High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2010, 28, 3709-3716.	1.6	106
6	Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. Journal of Nuclear Medicine, 2006, 47, 247-55.	5.0	88
7	Prognostic value of interim FDG PET/CT in Hodgkinâ€™s lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1064-1071.	6.4	87
8	Good clinical practice recommendations for the use of PET/CT in oncology. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 28-50.	6.4	85
9	Standardization of ¹⁸F-FDGâ€“PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 116-125.	1.6	85
10	Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1633-1642.	6.4	76
11	18F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas. Nuclear Medicine Communications, 2012, 33, 1089-1095.	1.1	71
12	FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. Haematologica, 2008, 93, 1269-1271.	3.5	70
13	Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT. EJNMMI Research, 2013, 3, 11.	2.5	67
14	Radioimmunoconjugates for the Treatment of Cancer. Seminars in Oncology, 2014, 41, 613-622.	2.2	65
15	Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery, 2007, 142, 952-958.	1.9	63
16	FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkinâ€™s lymphoma and Hodgkinâ€™s disease. Annals of Hematology, 2006, 85, 759-767.	1.8	61
17	Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and ⁶⁸Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial. Journal of Nuclear Medicine, 2016, 57, 1505-1511.	5.0	61
18	Revisiting the Robustness of PET-Based Textural Features in the Context of Multi-Centric Trials. PLoS ONE, 2016, 11, e0159984.	2.5	61

#	Article	IF	Citations
19	Delayed Gastric Emptying Scintigraphy in Cystic Fibrosis Patients Before and After Lung Transplantation. Journal of Heart and Lung Transplantation, 2006, 25, 1077-1083.	0.6	58
20	Fractionated ⁹⁰Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. Journal of Clinical Oncology, 2014, 32, 212-218.	1.6	57
21	Gastric scintigraphy with a liquidâ€“solid radiolabelled meal: performances of solid and liquid parameters. Nuclear Medicine Communications, 2004, 25, 1143-1150.	1.1	54
22	18F-fluorodeoxyglucoseâ€“positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. Annals of Oncology, 2011, 22, 705-711.	1.2	54
23	Tumor Immunotargeting Using Innovative Radionuclides. International Journal of Molecular Sciences, 2015, 16, 3932-3954.	4.1	51
24	Immuno-PET for Clinical Theranostic Approaches. International Journal of Molecular Sciences, 2017, 18, 57.	4.1	50
25	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. Blood, 2021, 137, 2307-2320.	1.4	48
26	Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Haematologica, 2008, 93, 390-397.	3.5	45
27	99mTc-MIBI pinhole SPECT in primary hyperparathyroidism: comparison with conventional SPECT, planar scintigraphy and ultrasonography. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 637-643.	6.4	44
28	Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture. Cancers, 2019, 11, 1282.	3.7	43
29	Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1270-1278.	6.4	42
30	Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study. Blood, 2019, 134, 692-692.	1.4	42
31	A pretargeting system for tumor PET imaging and radioimmunotherapy. Frontiers in Pharmacology, 2015, 6, 54.	3.5	41
32	Pretargeting for imaging and therapy in oncological nuclear medicine. EJNMMI Radiopharmacy and Chemistry, 2017, 2, 6.	3.9	41
33	90 Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematology,the, 2015, 2, e108-e117.	4.6	36
34	Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1005-1015.	6.4	35
35	Interest of Pet Imaging in Multiple Myeloma. Frontiers in Medicine, 2019, 6, 69.	2.6	34
36	Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer, 2010, 116, 1093-1100.	4.1	33

#	Article	IF	Citations
37	Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. Lancet Haematology,the, 2017, 4, e35-e45.	4.6	33
38	Radioimmunotherapy for Treatment of Acute Leukemia. Seminars in Nuclear Medicine, 2016, 46, 135-146.	4.6	31
39	Potential for Nuclear Medicine Therapy for Glioblastoma Treatment. Frontiers in Pharmacology, 2019, 10, 772.	3.5	31
40	Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. Haematologica, 2020, 105, e33-e36.	3.5	31
41	Radioimmunotherapy of B-cell non-Hodgkinâ€™s lymphoma. Frontiers in Oncology, 2013, 3, 177.	2.8	30
42	Improvement of Radioimmunotherapy Using Pretargeting. Frontiers in Oncology, 2013, 3, 159.	2.8	30
43	18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study. Bone Marrow Transplantation, 2014, 49, 131-137.	2.4	30
44	Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. Frontiers in Medicine, 2015, 2, 84.	2.6	29
45	Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma. Oncotarget, 2018, 9, 9061-9072.	1.8	29
46	Prospective comparison of two gamma probes for intraoperative detection of 18F-FDG: in vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrence. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1556-1562.	6.4	27
47	Radioimmunoconjugates for treating cancer: recent advances and current opportunities. Expert Opinion on Biological Therapy, 2017, 17, 813-819.	3.1	27
48	Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma. Cancer, 2010, 116, 1053-1058.	4.1	25
49	Clinical NECR in 18F-FDG PET scans: optimization of injected activity and variable acquisition time. Relationship with SNR. Physics in Medicine and Biology, 2014, 59, 6417-6430.	3.0	25
50	Vertebral Osteomyelitis: An Unusual Presentation of Bartonella henselae Infection. Seminars in Arthritis and Rheumatism, 2011, 41, 511-516.	3.4	24
51	Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients. Bone Marrow Transplantation, 2011, 46, 393-399.	2.4	24
52	Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of Î”SUVmax in the FDG-Avid Patients of the IMAJEM Study. Clinical Cancer Research, 2018, 24, 5219-5224.	7.0	24
53	PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. International Journal of Molecular Sciences, 2017, 18, 445.	4.1	23
54	What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model. International Journal of Molecular Sciences, 2019, 20, 2564.	4.1	22

#	Article	IF	Citations
55	Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis. International Journal of Computer Assisted Radiology and Surgery, 2020, 15, 129-139.	2.8	22
56	Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma. PLoS ONE, 2017, 12, e0183841.	2.5	22
57	Report of the 6th International Workshop on PET in lymphoma. Leukemia and Lymphoma, 2017, 58, 2298-2303.	1.3	21
58	Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches. Frontiers in Medicine, 2019, 6, 124.	2.6	20
59	Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials. Blood, 2018, 132, 257-257.	1.4	20
60	Comparative Toxicity and Efficacy of Combined Radioimmunotherapy and Antiangiogenic Therapy in Carcinoembryonic Antigenâ€“Expressing Medullary Thyroid Cancer Xenograft. Journal of Nuclear Medicine, 2010, 51, 624-631.	5.0	19
61	<scp>BCR</scp>â€<scp>ABL</scp>1 molecular remission after ⁹⁰<scp>Y</scp>â€epratuzumab tetraxetan radioimmunotherapy in <scp>CD</scp>22⁺<scp>P</scp>h⁺<scp>B</scp>â€<scp>ALL</scp>: proof of principle. European Journal of Haematology, 2013, 91, 552-556.	2.2	19
62	Prognostic Value and Clinical Impact of 18FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy. Frontiers in Medicine, 2014, 1, 54.	2.6	17
63	Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials. Cancers, 2020, 12, 2532.	3.7	17
64	¹⁸F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients. Journal of Nuclear Medicine, 2018, 59, 1380-1385.	5.0	15
65	Interest of FDG-PET in the Management of Mantle Cell Lymphoma. Frontiers in Medicine, 2019, 6, 70.	2.6	13
66	Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma. International Journal of Molecular Sciences, 2020, 21, 5406.	4.1	13
67	Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study. Blood, 2012, 120, 152-152.	1.4	13
68	Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study. Journal of Nuclear Medicine, 2021, 62, 1221-1227.	5.0	12
69	Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18FDG PET-CT. Oncotarget, 2018, 9, 27502-27513.	1.8	12
70	Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients. Leukemia and Lymphoma, 2019, 60, 222-225.	1.3	11
71	Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients. Blood, 2010, 116, 2875-2875.	1.4	10
72	[18F]-Fludarabine for Hematological Malignancies. Frontiers in Medicine, 2019, 6, 77.	2.6	9

#	Article	IF	Citations
73	Comparison of gastric emptying scintigraphy based on the geometric mean of the gastric proportion of the abdominal radioactivity or on the geometric mean of the intragastric radioactivity. Nuclear Medicine Communications, 2006, 27, 431-437.	1.1	8
74	Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases. Biomedicines, 2020, 8, 548.	3.2	8
75	ImmunoPET in Multiple Myelomaâ€"What? So What? Now What?. Cancers, 2020, 12, 1467.	3.7	8
76	Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma. Cancers, 2020, 12, 486.	3.7	8
77	Whole-body MR imaging in suspected physical child abuse: comparison with skeletal survey and bone scintigraphy findings from the PEDIMA prospective multicentre study. European Radiology, 2021, 31, 8069-8080.	4.5	8
78	Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients. Biology of Blood and Marrow Transplantation, 2019, 25, 906-911.	2.0	6
79	FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?. Cancers, 2020, 12, 1384.	3.7	6
80	Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, Conducted on Behalf of the Lysa Group. Blood, 2015, 126, 335-335.	1.4	6
81	Prognostic value of FDGâ€PET/CT response for patient selection before chimeric antigen receptorâ€Tâ€cells therapy in nonâ€Hodgkin lymphoma. Hematological Oncology, 2022, 40, 796-800.	1.7	6
82	Ã‰valuation de la rÃ©ponse thÃ©rapeutique par tomographie par Ã©mission de positons (TEP) au 18fluoro-dÃ©soxyglucose (FDG) en oncologie-hÃ©matologie. Medecine Nucleaire, 2011, 35, 600-607.	0.2	5
83	Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial. Blood, 2012, 120, 906-906.	1.4	5
84	Molecular Signature of ¹⁸F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study. Journal of Nuclear Medicine, 2022, 63, 1008-1013.	5.0	4
85	Therapeutic Immunoconjugates. Which Cytotoxic Payload: Chemotherapeutic Drug (ADC) or Radionuclide (ARC) ?. Current Cancer Therapy Reviews, 2016, 12, 54-65.	0.3	3
86	Radioimmunotherapy of Lymphomas. , 2019, , 113-121.		3
87	Apport de la TEP/TDM au 18FDG dans la stadification initiale et lâ€™Ã©valuation prÃ©coce de la rÃ©ponse thÃ©rapeutique des rhabdomyosarcomes pÃ©diatriques. Medecine Nucleaire, 2010, 34, 655-663.	0.2	2
88	FDG PET in Multiple Myeloma. , 2019, , 27-38.		2
89	Cardiac Metastasis from Medullary Thyroid Cancers with Long-Term Survival under Vandetanib. European Thyroid Journal, 2021, 10, 1-6.	2.4	2
90	La radio-immunothÃ©rapie en clinique. Medecine Nucleaire, 2008, 32, 254-257.	0.2	1

#	Article	IF	Citations
91	Lâ€™immuno-TEP, une nouvelle approche dâ€™imagerie molÃ©culaire. Medecine Nucleaire, 2010, 34, 295-298.	0.2	1
92	RadiothÃ©rapie vectorisÃ©eÂ: les nouvelles molÃ©cules. Medecine Nucleaire, 2011, 35, 613-616.	0.2	1
93	Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90-Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan. Medical Radiology, 2012, , 551-556.	0.1	1
94	Prospects for Enhancing Efficacy of Radioimmunotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 139-153.	0.1	1
95	18F-FDG PET/CT in multiple myeloma: critical insights and future directions. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1048-1050.	6.4	1
96	FDG-PET Predicts Response to Fractionated Radioimmunotherapy with 90Y-Epratuzumab Anti-CD22 MAB in Patients with NHL.. Blood, 2005, 106, 4782-4782.	1.4	1
97	Respective PROGNOSTIC Value of the International Harmonization PROJECT (IHP), Gallamini and London Criteria for Interim FDG PET-CT Performed AFTER 4 Courses of ABVD IN HODGKIN'S LYMPHOMA. Blood, 2010, 116, 3889-3889.	1.4	1
98	La place deÂlaÂTEP auÂFDG dansÂl'Ã©valuation desÂlymphomes. Hematologie, 2009, 15, 305-312.	0.0	0
99	La radio-immunothÃ©rapie. Medecine Nucleaire, 2009, 33, 148-151.	0.2	0
100	Consolidation par 90Y-epratuzumab en fractionnÃ© dans le lymphome B diffus Ã grandes cellulesÂ: rÃ©sultats prÃ©liminaires dâ€™une Ã©tude de phase II. Medecine Nucleaire, 2011, 35, 478-486.	0.2	0
101	ModÃ©lisation du taux de comptage en TEP Ã partir de donnÃ©es cliniquesÂ: une voie robuste pour lâ€™optimisation des paramÃ¨tres dâ€™acquisitionÂ?. Medecine Nucleaire, 2012, 36, 209-214.	0.2	0
102	Les outils de mÃ©decine nuclÃ©aire pour le dÃ©veloppement de la mÃ©decine personnalisÃ©e dans le cancer du sein. Medecine Nucleaire, 2012, 36, 233-236.	0.2	0
103	La place de la TEP au FDG dans lâ€™Ã©valuation des lymphomes en 2012. Diagnostic and Interventional Imaging, 2013, 94, 164-174.	0.0	0
104	SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for Human. Frontiers in Oncology, 2020, 10, 20.	2.8	0
105	Efficacy of FDG-PET/CT Imaging To Guide Biopsies in the Detection of Richterâ€™s Syndrome.. Blood, 2007, 110, 1390-1390.	1.4	0
106	Reply to E. Laffon et al.. Haematologica, 2020, 105, e42-e42.	3.5	0
107	Genome-Wide Transcriptome Analysis Identifies Molecular Patterns of FDG-PET/CT Biomarkers in MM Patients from the Cassiopet Study. Blood, 2020, 136, 26-26.	1.4	0
108	Radionuclide Metabolic Therapy. , 2013, , .		0